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Background: Human xylosyltransferase-I (XT-I) catalyzes the rate-limiting step in proteoglycan glycosylation. An increase
in XYLT1 mRNA expression and serum XT activity is associated with diseases characterized by abnormal extracellular
matrix accumulation like, for instance, fibrosis. Nevertheless, physiological and pathological mechanisms of transcriptional
XT regulation remain elusive.
Results: To elucidate whether promoter variations might affect the naturally occurring variability in serum XT activity, a
complete sequence analysis of the XYLT1 promoter was performed in genomic DNA of healthy blood donors. Based on
promoter amplification by a specialized PCR technique, sequence analysis revealed a fragment of 238 bp, termed
XYLT1238*, which has never been described in the human XYLT1 reference sequence so far. In silico characterization of
this unconsidered fragment depicted an evolutionary conservation between sequences of Homo sapiens and Pan
troglodytes (chimpanzee) or Mus musculus (mouse), respectively. Promoter activity studies indicated that XYLT1238*
harbors various transcription factor binding sites affecting basal XYLT1 expression and inducibility by transforming
growth factor-β1, the key fibrotic mediator.
A microsatellite and two single nucleotide variants (SNV), c.-403C>T and c.-1088C>A, were identified and genotyped in
100 healthy blood donors. Construct associated changes in XYLT1 promoter activity were detected for several sequence
variants, whereas serum XT activity was only marginally affected.
Conclusions: Our findings describe for the first time the entire XYLT1 promoter sequence and provide new insights into
transcriptional regulation of XT-I. Future studies should analyze the impact of regulatory XYLT1 promoter variations on
XT-associated diseases.
Keywords: Xylosyltransferase, Promoter, Single-nucleotide variant, Microsatellite, Gene regulationBackground
The isoenzymes human xylosyltransferase-I and -II (XT-
I/-II; EC 2.4.2.26) catalyze the key step of glycosaminogly-
can biosynthesis by transferring activated UDP-xylose to
selected serine residues on a proteoglycan core-protein in
the golgi [1,2]. Proteoglycans are components of the extra-
cellular matrix (ECM) responsible for tissue stabilization,
hydration and efficient functionality of various signal
transduction pathways [3,4].
In fibrosis, a dysbalance of matrix synthesis and de-
gradation results in abnormal matrix accumulation,
which initiates the functional loss of the affected organ.
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unless otherwise stated.processes, as well as their molecular mechanisms are
described, no anti-fibrotic treatment could be developed
until now [5,6]. Among others, an increased XYLT1
mRNA expression, as well as XT secretion and serum
activity could be shown to be associated with a rise in
myofibroblast differentiation and matrix synthesis in
liver fibrosis, skin fibrosis or dilated cardiomyopathy
[7-10]. Recently, dysregulations of XT have also been
connected with the manifestation of osteoarthritis or
disorders of ossification [11-13].
XT-I and -II, encoded by the genes XYLT1 and XYLT2,
are characterized by slight differences in their substrate
specificities. Nevertheless, they are distinguishable by their
local tissue expression patterns [14,15]. Based on the hy-
pothesis that XT are pivotal regulators of pathobiochemis-
try, current studies address the analysis of their regulatory
mechanisms. With regard to transcriptional control, twotd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[9,11]. Unfortunately, due to their wide-spread scope,
none of these proteins represents an adequate point of
therapeutic application. Thus, it is of great importance to
identify additional basic pathways of XT regulation.
So far, XYLT1 and XYLT2 promoter regions have been
initially identified and characterized. It could be de-
monstrated that both regions miss common eukaryotic
promoter elements like a TATA- or CAAT-box, contain
highly GC-rich passages upstream of the translational
start site and are controlled by transcription factors of
the AP- and SP-family [16,17]. Due to the highly GC-
rich template, XYLT1 promoter characterization was
based on gene synthesis referring to the XYLT1 reference
sequence [GenBank Accession Number NG_015843.1].
Therefore, neither the XYLT1 promoter conservation
nor the occurrence of its sequence variants was formerly
defined.
The aim of this study was to analyze whether naturally
occurring promoter sequence variants like single nucleo-
tide variants (SNV) could play an emerging role in XYLT1
transcriptional regulation. A microsatellite and two SNV
were identified and genotyped in genomic DNA of 100
healthy blood donors, although these variants exerted only
marginal effects on serum XT activity. Nevertheless, the
SNV c.-1088C>A significantly reduced promoter activity.
In addition to SNV screening, we identified and character-
ized an evolutionary conserved fragment of 238 bp in the
XYLT1 promoter region which has never been described
in the published XYLT1 human reference sequence so far.
In summary, this is the first study defining and charac-
terizing the variability of the complete XYLT1 promoter
sequence in the general population which in turn exten-
sively enlarges our insights in promoter organization and
transcriptional regulation of human XT-I.
Methods
Study subjects and collection of blood samples
For this study, EDTA plasma and serum samples of 100
healthy blood donors (50% males; 18-60 years of age;
mean age +/- SD: 36.2 +/- 13.5 years) were collected. The
experimental design and research has been performed in
accordance with the Declaration of Helsinki and was ap-
proved by the local ethics committee (medical faculty,
Ruhr-Universität Bochum, Bad Oeynhausen, Germany).
All blood donors gave their informed consent.
DNA extraction and XYLT1 promoter amplification
After plasma centrifugation, genomic DNA was extracted
from 200 μL EDTA blood leukocytes using the Nucleo
Spin Blood Kit (Macherey-Nagel). Referring to the current
XYLT1 reference sequence [GenBank Accession Number
NG_015843.1], the promoter region was divided into four
overlapping fragments termed D (c.-1689 to c.-1273), C(c.-1385 to c.-813), B (c.-891 to c.-215) and A (c.-372 to
c. + 122). The amplification of fragments D, C and B was
performed by an initial denaturation step at 95°C (15 min)
followed by 35 cycles (denaturation at 95°C for 1 min, an-
nealing at optimal annealing temperature (TA) for 1 min
and elongation at 72°C for 1 min) and final elongation at
72°C for 15 min. All PCR and sequencing reactions were
run on thermocycler T professional (Biometra). Primer
sequences and TA are listed in Table 1. The reaction mix-
ture was composed of 11.15 μL water, 5.0 μL Q-Solution
(Qiagen), 0.25 μL dNTPs (25 mM), 2.5 μL reaction buffer
(Qiagen), 0.5 μL of each primer (25 μM), 5.0 μL template
(dilution 1:5) and 0.1 μL HotStar Taq DNA-polymerase
(Qiagen). The amplification of the GC-rich A fragment re-
quired highly specialized conditions. The used slowdown-
PCR cycling conditions are described elsewhere, while the
composition of the reaction mixture (15.8 μL water,
10.0 μL Q-Solution, 5.0 μL reaction buffer, 2.0 μL of each
primer (2.5 μM), 1.0 μL of dATP, dTTP and dCTP
(10 mM), 2.5 μL of dGTP (1 mM), 7.5 μL dc7GTP (1 mM;
Roche), 0.2 μL HotStar Taq DNA-polymerase and 2.0 μL
template) was adjusted [18,19].
Promoter sequencing, mutational analysis and
genotyping
Sanger sequencing was initiated by PCR product clean-
up. 5.0 μL of the PCR product were incubated with
2.0 μL of exonuclease I (NEB), as well as 2.0 μL shrimp
alkaline phosphatase (Affymetrix) at 37°C for 30 min
and 80°C for 15 min. 2.0 μL of the reaction mixture were
added to a sequencing master mix containing 5.5 μL
water, 5.0 μL Q-solution (Qiagen), 4.0 μL BigDye v3.1
sequencing premix (Life technologies), 2.0 μL 5 × BigDye
sequencing buffer (Life technologies) and 1.5 μL primer
(25 μM; listed in Table 1). Sequencing reaction started
with a denaturation step at 95°C for 2 min and run for
30 cycles (denaturation at 95°C for 10 s, annealing at TA
for 10 s, elongation at 60°C for 4 min). After purification
by a sephadex-G50 spin-column based protocol, se-
quences were analyzed by capillary electrophoresis using
the Genetic Analyzer 3500 (Life technologies).
Promoter construct cloning and insertion of SNV by site-
directed mutagenesis
Construction of pGL4.10 luciferase reporter vectors con-
taining the XYLT1 promoter fragments c.-1639 to c.+1Δ238*
or c.-1031 to c.+1Δ238*, according to the current uncom-
plete reference sequence, was described previously [16]. To
adjust the promoter length, we inserted the missing region
XYLT1238* using the QuikChange site-directed mutagenesis
kit (Agilent). XYLT1238* was amplified from the PCR prod-
uct of the A fragment (primers are listed in Table 1) and
purified by the MSB Spin PCRapace kit (Stratec). Site-
directed mutagenesis cycling conditions and composition
Table 1 Primers used for amplification, sequencing and site-directed mutagenesis (SDM) of XYLT1 promoter fragments
Application Primer sequence (5′→ 3′) TA [°C]
PCR and sequencing Fragment A CCCTGTTTCGCGGCCCCTG Slowdown-PCR
CCGGAGTCGAGGCTGCTGAA
Fragment B1 ATGGATGGGGAAAAGGACAC 58.8
TGGGGGAGGAGCCGAGGGAG
Fragment B2 CAGTCAGGATGGGAAAGAAC 58.8
GGTGCCAACGATGTACTAAG
Fragment C AACAATCTCTTCCCACTCCC 61.2
GGAGTTACTCAACCTTCGCA
Fragment D CATGCCCGGCTAATTTTTGT 61.2
CTTCGCATCTTGTCTGCTGT








Mutated bases are marked in bold.
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sert single nucleotide sequence variants in the synthesized
vector construct c.-1031 to c.+1complete, site-directed muta-
genesis was applied according to the manufacturer’s in-
structions (primers are listed in Table 1). Successful
insertion of XYLT1 promoter fragment or single base ex-
change was checked by amplification and sequencing of the
appropriate plasmid region or direct plasmid sequencing
using vector specific primers (Table 1).
Cell culture and transient transfection of plasmids
SW1353 chondrosarcoma cells were routinely grown in
RPMI 1640 medium (Life technologies), supplemented with
10% FCS (Pan biotech) and 1% antibiotic/antimycotic solu-
tion (PAA). For transfection, 180000 cells were seeded in
triplicate in 6 well culture dishes and incubated for 24 h.
The next day, 188 μL medium (without any supplements)
were mixed with 12 μL FuGene 6 transfection reagent
(Promega) and incubated at RT for 5 min. After addition of
1 μg of the appropriate pGL4.10 plasmid and 10 ng of
pGL4.74, the reaction mixture was incubated for 30 min
and applied to the cells. After 24 h, the cell culture medium
was replaced. Where appropriate, TGF-β1 (7.5 ng/mL,
Miltenyi Biotech) was added. Cells were harvested in 500 μL
lysis buffer and promoter activity was analyzed after 48 h.
Dual luciferase reporter assay
Cellular luciferase activity was assayed with the Dual
Luciferase Reporter assay system (Promega) on a LumatLB9705 luminometer (EG&G). 20 μL lysate were incu-
bated with 100 μL LARII substrate to stimulate substrate
turnover of firefly luciferase (encoded by the pGL4.10 vec-
tor construct upstream of the XYLT1 promoter sequence).
Addition of 100 μL Stop&Glo solution inhibited firefly lu-
ciferase and simultaneously induced substrate turnover of
renilla luciferase (encoded by the co-transfected pGL4.74
vector). To calculate relative luciferase activity represen-
ting promoter activity, firefly luciferase activity was mea-
sured in each sample and normalized to renilla luciferase
activity. Normalization reduced the impact of differences
in efficiency of transfection or lysis.
XT activity assay
Determination of serum XT activity was performed as
described before. The method relies on incorporation of
14[C] D-xylose (Du Pont) into silk fibroin receptor pro-
tein. Measured disintegrations per minute (dpm) are
proportional to enzymatic activity [21,22].
In silico analysis
In silico analysis of transcription factor binding sites was
carried out using the Genomatix online software suite,
while sequence alignments were performed with Clone
Manager 9.0 (Scientific & Educat. Software) and ClustalW
(DNA Star Inc.). Evaluation of LD maps and haplotype
frequencies was carried out using Haploview 4.0 (Broad
Institute) [23]. Blocks were defined according to the “solid
spine of LD” setting in the software.
Figure 1 (See legend on next page.)
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Figure 1 Sequence alignment of human genomic XYLT1 promoter sequences (c.-610 to c.+122). The sequence examined in this study
(XYLT1complete, [GenBank Accession Number KM079589]) was compared with the appropriate XYLT1 promoter region of the current human
reference sequence [GenBank Accession Number NG_015843.1] and a human shotgun sequence [GenBank Accession Number NW_001838365.2].
Numbers indicate the nucleotide position up- or downstream of the translation initiation site ATG (red color). Matching nucleotides are shaded in
yellow, whereas XYLT1238* (c.-363 to c.-126) is marked in bold.
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Experimental data were analyzed by Mann-Whitney-U-
Test using GraphPad Prism 5.0 (GraphPad Software). p
values less than 0.05 were considered statistically signifi-
cant. To examine whether genotype distributions fit into
the Hardy-Weinberg equilibrium, a χ2-test was performed.Results
Sequence analysis of the human XYLT1 promoter region
To screen for natural occurring variants in the XYLT1 pro-
moter, we performed a preliminary sequence analysis of
the genomic DNA of ten healthy blood donors. Referring
to the published XYLT1 reference sequence [GenBank
Accession Number NG_015843.1], the amplification was
performed by splitting the region into four fragments, A to
D. Due to a high GC-content of 75%, the A fragment
(c.-372 to c.+122), could exclusively be amplified by
slowdown-PCR conditions. Sequencing results demon-
strated that the XYLT1 promoter region does not comprise
just 1639 bp, as published earlier [16] but also harbors an
additional fragment of 238 bp in between the known se-
quence of the A fragment. The nucleotide sequence for
the A fragment has been deposited in the GenBank data-
base [GenBank Accession Number KM079589].
The identification of this hitherto undescribed XYLT1
promoter fragment, termed XYLT1238*, was verified by se-
quencing the genomic DNA of 100 healthy blood donors.
All PCR products spanned approximately 700 bp, so none
of the amplificates displayed the calculated fragment
length of 494 bp, referring to the current XYLT1 reference
sequence [GenBank Accession Number NG_015843.1]. A
sequence alignment of the reference sequence, as well as
the consensus sequence of the XYLT1 promoter sequence
XYLT1complete, identified in this study, confirmed the ab-
sence of XYLT1238* in the published reference sequence
(Figure 1). In the following, base numbering depends on
promoter sequence XYLT1complete, whereby the first nu-
cleotide of the translation initiation start site was defined
as c.+1 and promoter nucleotides were numbered back-
wards. XYLT1238* was located at position c.-363 to c.-126.
By screening data bases for complementary human DNA
reference sequences, in silico analysis revealed the depos-
ition of only one shotgun sequence [GenBank Accession
Number NW_001838365.2] conforming to XYLT1238*.
However, due to a sequence cut off at position c.-162,
XYLT1238* is merely partially listed (Figure 1).An evolutionary species alignment of the PCR A frag-
ment (c.-610 to c.+122) represented a strong overlap of
human promoter sequence XYLT1complete [GenBank Ac-
cession Number KM079589] with corresponding DNA
fragments of related species Pan troglodytes [GenBank
Accession Number NC_006483.3] and Mus musculus
[GenBank Accession Number NC_000073.6]. While the
compliance of the whole genomic XYLT1 promoter se-
quences between Homo sapiens (c.-1877 to c. + 1) and Pan
troglodytes assessed as 98%, the compliance of XYLT1238*
(c.-363 to c.-126) was 93% (Figure 2). Corresponding se-
quence conformity of Homo sapiens and Mus musculus
sequences amounted to 58% in the whole and to 77% con-
cerning XYLT1238*.
Characterization of the XYLT1 promoter fragment
XYLT1238*
XYLT1238* displays a GC content of 84.9% and harbors a
variable microsatellite region (c.-201 to c.-148). To iden-
tify putative transcription factor binding sites, an in
silico analysis was performed. Search criteria were re-
stricted to families of transcription factors, which have
been discussed to modulate XT or which are known me-
diators of TGF-β1. As indicated in Figure 3, several tran-
scription factor binding sites of transcriptions factor
families SP1F (GC-box factors, specificity protein1),
EGRF (early growth response/nerve growth factor in-
duced protein C and related factors) and KLFS (krueppel
like transcription factors) were identified.
To evaluate the influence of XYLT1238* on promoter ac-
tivity, appropriate promoter luciferase constructs were
cloned by insertion of XYLT1238* in existing XYLT1
promoter coding luciferase vectors using site-directed mu-
tagenesis. These plasmid constructs were originally syn-
thesized for initial promoter characterization [16] and
include the entire, but as we could define incomplete, pro-
moter region c.-1639 to c.+1Δ238* or the most active pro-
moter segment c.-1031 to c.+1Δ238* according to the
XYLT1 reference sequence [GenBank Accession Number
NG_015843.1]. After plasmid transfection into SW1353
chondrosarcoma cells and subsequent performing of a
dual luciferase assay, promoter activity was shown to be-
come significantly upregulated by insertion of XYLT1238*.
Comparing promoter activity of constructs c.-1639 to
c.+1Δ238* and c.-1031 to c.+1Δ238* to the vectors c.-1639 to
c.+1complete and c.-1031 to c.+1complete revealed a signifi-
cant increase of 22.6% (±0.9% SEM) to 81.6% (±5.6%
Figure 2 (See legend on next page.)
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Figure 2 Cross-species sequence alignment of the XYLT1 promoter sequence c.-610 to c.+122. Genomic DNA sequences of Homo sapiens
(XYLT1complete, [GenBank Accession Number KM079589]), Pan troglodytes [GenBank Accession Number NC_006483.3] and Mus musculus [GenBank
Accession Number NC_000073.6] have been compared. Numbers indicate the nucleotide position up- or downstream of the translation initiation
site ATG (red color). Matching nucleotides are shaded in yellow, whereas XYLT1238* (c.-363 to c.-126) is marked in bold.
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spectively (Figure 4, white bars). To analyze the putative
inducibility of the XYLT1 promoter activity by TGF-β1,
SW1353 cells were transfected as described above,
followed by incubation with cell culture medium supple-
mented with TGF-β1 for 48 h. While no increase in pro-
moter activity was detected for constructs c.-1639 to
c.+1Δ238* and c.-1031 to c.+1Δ238* in comparison to un-
treated controls, promoter activity of constructs c.-1639 to
c.+1complete and c.-1031 to c.+1complete enlarged from
100% (±1.1% SEM) to 120.2% (±16.2% SEM) or 81.6%
(± 5.6% SEM) to 101.7% (±3.2% SEM), respectively
(Figure 4, black bars).
SNV analysis
In addition to identification of XYLT1238*, genotyping of
the complete promoter region revealed two SNV. Allele
frequencies of c.-403C>T and c.-1088C>A were deter-
mined in DNA samples of 100 healthy blood donors
(Table 2). All genotype distributions accorded with the
Hardy-Weinberg equilibrium, whereas haplotype ana-
lysis depicted a weak linkage disequilibrium (D’ = 0.85;
r2 = 0.49; haplotypes Table 3).
By performing an in silico analysis, it could be demon-
strated that the base exchange c.-1088C>A entails theFigure 3 Localization of transcription factor binding sites in XYLT1238
position downstream of the translation initiation site (ATG). XYLT1238* (c.-36
are highlighted in black (SP1F), blue (EGRF) or green (KLFS).presence of a SMAD3 transcription factor binding site
(reverse strand; 5′-GTCTGG-3’). After selective mu-
tation of the cloning luciferase vector c.-1031 to
c.+1complete by site-directed mutagenesis according to the
SNV genotype, SNV associated changes in promoter activ-
ity were analyzed (Figure 5). c.-403T did not exert any
influence on promoter activity, whereby the mutation
c.-1088A was followed by a significant reduction in activ-
ity to 48.1% (± 3.0% SEM). Contrarily, quantification of
serum XT activity did not reveal any association between
SNV genotype and serum XTactivity (data not shown).
Identification and characterization of a microsatellite in
the XYLT1 promoter region
XYLT1238* characterization also uncovered a variable
microsatellite (c.-201 to c.-148). Genotyping of 100 healthy
blood donors revealed that 55% of blood donors were het-
erozygous carriers of this microsatellite, while 45% were
homozygous carriers. In addition to the wildtype, five
homozygous variants of the microsatellite were identified,
distinguishable by different numbers of tandem repeats
(GGX)n (Figure 6). Allele frequencies are listed in Table 4.
The more tandem repeats were coded in the microsatellite
variant, the more EGR-1 transcription factor binding
sites are strung together (Figure 3). Due to sequence* and appropriate flanking regions. Numbers indicate the nucleotide
3 to c.-126) is marked in bold, while transcription factor binding sites









+ TGF-  1 (7.5 ng/mL)
negative control
***
relative promoter activity  [%]
***
***
Figure 4 Influence of XYLT1238* on promoter activity. Changes in relative promoter activity of pGL4.10 XYLT1 promoter cloning constructs
were determined in response to insertion of XYLT1238* by site-directed mutagenesis. Promoter activities are expressed relative to the activity of
construct c.-1031 to c.+1complete, which was defined as 100%. Plasmids were transfected into SW1353 cells and promoter activity was determined
in lysates of untreated (white bars) or TGF-β1 induced (black bars) cells by dual luciferase assay. Values are means ± SEM of triplicates from at least
two or three independent experiments. ns = not significant; **p < 0.01; ***p < 0.001 (Mann-Whitney U-test).
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finable neither by Sanger nor by pyro sequencing.
Referring to SNV analysis, we also tested the influence
of microsatellite variants on promoter activity. For this
purpose, variants were cloned into the luciferase promoter
construct c.-1031 to c.+1complete by site-directed mutagen-
esis. Determination of relative promoter activity by dual
luciferase assay in SW1353 cells depicted no dependency
of tandem repeat length on promoter activity (Figure 7).
Nevertheless, construct associated changes in promoter
activity were detected. In addition to basal promoter ac-
tivity, inducibility of microsatellite variant constructs by
TGF-β1 was analyzed. Although the promoter activity of
all constructs was significantly increased, no obvious trend
in construct associated promoter activity difference was
identifiable.
Discussion
The aim of this study was to figure out transcriptional
regulation mechanisms of XT-I. Therefore, the genomic
DNA of healthy blood donors was screened for sequence
variants in the human XYLT1 promoter region to deter-
mine their influence on the naturally occurring variabil-
ity of serum XT activity and to evaluate the promoter
conservation. XT-I, the key enzyme of proteoglycan syn-
thesis, is not only upregulated in the case of fibrotic re-
modeling, but is also associated with osteoarthritis and
ossification disorders [11,12,24]. The clinical relevanceTable 2 Allele frequencies of XYLT1 promoter SNV
detected in healthy blood donors
SNV rs ID Allele Frequency
c.-403C>T rs118030014 C 104/200 (0.52)
T 96/200 (0.48)
c.-1088C>A rs59423557 C 124/200 (0.62)
A 76/200 (0.38)of XT-I is based on its capability to represent the proteo-
glycan turn-over rate as a serum biomarker [25]. Hence,
an increasing knowledge of its transcriptional regulation
pathways will contribute to the elucidation of underlying
pathomechanisms.
At present, only two publications concern the human
XYLT1 promoter region. One of them describes the ini-
tial promoter identification and characterization. Due to
the high GC content, cloning was based on gene synthe-
sis of the first 600 bp upstream of the translational start
codon according to the current XYLT1 reference se-
quence [GenBank Accession Number NG_015843.1]
[16]. Another research project deals with the investiga-
tion of XYLT1 promoter activity regulation by IL-1β. As
indicated, promoter deletion constructs were cloned by
single fragment promoter amplification [26].
In this study, the first sequence analysis of the
complete XYLT1 promoter region was performed. Sur-
prisingly, we were not able to fully reproduce the current
XYLT1 reference sequence [GenBank Accession Number
NG_015843.1] but rather found out that the XYLT1 pro-
moter is larger than expected and harbors a hitherto
undescribed fragment of 238 bp, termed XYLT1238*
[GenBank Accession Number KM079589]. To confirm
this, we performed an in silico analysis revealing undeni-
able compliance of one single human shotgun sequence
[GenBank Accession Number NW_001838365.2]. Inter-
ruption of the shotgun sequence reflects severity inTable 3 Estimated XYLT1 haplotypes detected in healthy
blood donors
Haplotype c.-403 c.-1088 Frequency
1 C C 98/200 (0.492)
2 T A 70/200 (0.352)
3 T C 26/200 (0.128)
4 C A 6/200 (0.028)
0 20 40 60 80 100 120
c.-1031 +1  [c.-1088C>A]complete
c.-1031 +1  [c.-403C>T]complete
c.-1031 +1complete
empty vector
relative promoter activity  [%]
***
ns
Figure 5 Influence of SNV on promoter activity. Changes in relative promoter activity of pGL4.10 XYLT1 promoter cloning construct c.-1031 to
c.+1complete were determined in response to SNV-associated base exchange by site-directed mutagenesis. Promoter activities are expressed
relative to the activity of construct c.-1031 to c.+1complete, which was defined as 100%. Plasmids were transfected into SW1353 cells and promoter
activity was determined by dual luciferase assay. Values are means ± SEM of triplicates from at least two or three independent experiments.
ns = not significant; ***p < 0.001 (Mann-Whitney U-test).
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cessful amplification was only achievable by choosing
slowdown-PCR conditions [18,19]. Molecular circum-
stances causing difficulties in amplification are uncertain.
Speculatively, DNA secondary structures are involved in
complex DNA assembly. We identified a potential struc-
ture of a G-quadruplex in the XYLT1 promoter (c.-387 to
c.-364). G-quadruplex elements are known to influence
transcriptional regulation and may be loosened by
addition of PCR amplification additives in vitro [27,28].
Here, dc7GTP was used to minimize hogsteen base pairing
in the G-quadruplex structure [29].
However, a high percentage match was detected by a
cross-species alignment of the complete human XYLT1
promoter sequence XYLT1complete described here with se-
quences of Pan troglodytes [GenBank Accession Number
NC_006483.3] and Mus musculus [GenBank Accession
Number NC_000073.6]. Based on the evolutionary simi-
larity of Homo sapiens and Pan troglodytes genomes [30],
the reported promoter sequence XYLT1complete becomes
strongly reinforced. Thus, we suggest a revision of the
current XYLT1 reference sequence.
Characterization of XYLT1238* demonstrated a critical
influence on basal transcriptional activity, as well asFigure 6 Microsatellite sequence variants. Naturally occurring variants o
c.-145 indicates the nucleotide position upstream of the translation initiatio
pattern. Matching nucleotides between variants are shaded in yellow. Theinducibility of XT-I by TGF-β1. Until now, studies have
described an induction of XYLT1 mRNA expression in fi-
brotic tissues or after incubation of cultivated cells with
TGF-β1 [9,10], whereas induction of promoter activity has
remained elusive. Hence, this is the first study unravelling
transcriptional mechanisms of XT-I induction. Several
mediators like, for instance, transcription factors of the
EGRF-, SP1- or KLFS-family were identified to regulate
transcription. They all are associable with the manifest-
ation of fibrotic disorders [31,32]. The most frequent tran-
scription factor binding site in XYLT1238*, which was
elicited in silico, binds EGR1 (early growth response pro-
tein 1). EGR1 functions as a downstream mediator of
TGF-β1 and is responsible for a SMAD-independent in-
crease in collagen mRNA expression in systemic sclerosis
[33,34].
Sequence analysis of the genomic DNA of 100 healthy
blood donors revealed the occurrence of a microsatellite
as well as two SNV in the XYLT1 promoter region, and
points to a strong conservation. This hypothesis is con-
firmed by the description of only a few SNV, representing
risk factors for proteoglycan-associated pathologies like
diabetic nephropathy, and two extremely rare, naturally
occurring defects in the XYLT1 gene so far [24,35,36]. Thef the XYLT1 promoter region c.-211 to c.-145 are illustrated. Numbering
n site, whereas numbers on the left indicate the tandem-repeat
microsatellite locus is highlighted in green.
Table 4 Allele frequencies of homozygous microsatellite
variants detected in healthy blood donors
Homozygous microsatellite variant Frequency
wildtype 27/45
+ 3 bp 5/45
- 3 bp 2/45
+ 6 bp 1/45
- 6 bp 9/45
- 18 bp 1/45
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was elucidated to evoke functional enzymatic alterations
causing intellectual disability and dwarfism [12]. In
addition, five XYLT1-mutations were identified in patients
suffering from Desbuquois dysplasia type 2, which is de-
fined by pathological ossification [13]. Therefore, strong
conservation of promoter and protein-coding genomic se-
quences of XYLT1 emphasizes its important physiological
function.
In terms of the detected, genetically unlinked, SNV c.-
403C>T and c.-1088C>A, a significant impairment of
promoter activity was associated with homozygous nu-
cleotide exchange c.-1088A. As indicated by in silico
analysis, the mutation suggests generation of a SMAD3
transcription binding site. Nevertheless, SMAD3 is a
cytoplasmatic mediator of TGF-β1 and should induce
rather than reduce XYLT1 promoter activity [37]. Thus,
the effect of c.-1088A on promoter activity should be
further verified. Contrarily, no association between SNV
genotypes and changes in serum XT activity of healthy
blood donors was obtained. Hence, the identified SNV
might contribute to differences in XYLT1 mRNA level
but did not impact enzyme activity. It must be further









Figure 7 Influence of microsatellite variants on promoter activity. Cha
construct c.-1031 to c.+1complete (wildtype) were determined in response to
Promoter activities are expressed relative to the activity of construct c.-1031
into SW1353 cells and promoter activity was determined in lysates of untre
assay. Values are means ± SEM of triplicates from at least two or three inde
***p < 0.001 (Mann-Whitney U-test).with changes in mRNA levels. Besides, XT-I may only
marginally contribute to cumulative serum XT activity.
This hypothesis is underlined by studies of Condac et
al., who recently postulated that XT-II is the predomin-
ant XT-isoenzyme in serum [38].
Concerning the microsatellite in the XYLT1 promoter
region, five homozygous variants were identified in
addition to the wildtype genotype. Microsatellites consist-
ing of (GGX)n tandem repeats are quite common in the
human genome, especially in 5′ untranslated regions [39].
Nevertheless, it has to be emphasized that 55% of screened
sequences were heterozygous, whereby corresponding al-
lele types could not be resolved by standard sequencing.
Future studies should deal with the exact genotyping. We
further investigated the influence of the microsatellite vari-
ants on transcriptional regulation. Referring to promoter
activity studies, a construct dependent variability of pro-
moter activity was detected. However, a dependency of
tandem repeat count was detected neither to basal nor
TGF-β1 induced expression. Similar results were obtained
by Akai et al., characterizing a microsatellite in the pro-
moter region of collagen type 2 (COL1A2) [40]. Whether
XYLT1 gene expression is significantly influenced by
microsatellite variants in vivo was not part of this study,
due to inappropriate cohort size, and needs to be further
evaluated.Conclusions
In summary, we describe here the first sequence analysis
of the human XYLT1 promoter region. Based on our find-
ings, we propose a revision of the current human XYLT1
promoter reference sequence. Our results provide new in-
sights into transcriptional XT-I regulation. In future, geno-








+ TGF-  1 (7.5 ng/mL)  
negative control
nges in relative promoter activity of pGL4.10 XYLT1 promoter cloning
insertion of microsatellite variants by site-directed mutagenesis.
to c.+1complete, which was defined as 100%. Plasmids were transfected
ated (white bars) or TGF-β1 induced (black bars) cells by dual luciferase
pendent experiments. ns = not significant; *p < 0.05; **p < 0.01;
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http://www.biomedcentral.com/1471-2156/15/129might uncover a potentially link between pathologic XT
regulation and XYLT1 promoter sequence variants.
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